

**Freedom of Information Request**

**Ref: 22-541**

3 October 2022

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

**(1) Drug Patient Level Contract Monitoring (DrPLCM) report**

**Data fields from the DrPLCM report, as specified in table 1 (below). Please do not send patient IDs or cost data, as I appreciate this would compromise data privacy and commercial sensitivity.**

Please see the attached Drug Patient Level Contract Monitoring report

**(2) SACT Cancer report**

**An extract from the chemotherapy ePMA system showing patients treated by drug and diagnosis, as specified in table 2 (below). Please also address the questions in section 3 which aims to give me top level information on the number of patients treated for different types of breast cancer.**

Please see the attached SACT Cancer report

**(3) Breast Cancer information**

**I am interested to know the total number of patients with breast cancer treated with medicines between Apr 2022 and Aug 2022. When responding to the questions below please count all patients treated with chemotherapies, biological agents, hormonal therapies etc., but exclude patients treated with surgery only and/or radiotherapy only.**

**1. How many patients with breast cancer were treated in total?**

214. This figure is patients starting a new treatment with any anti-cancer drug for breast cancer, including subsequent treatments, between 01/04/22 and 31/07/22

**2. How many patients with breast cancer were treated at the following stages?**

- o Early breast cancer (stages I or II)**
- o Locally advanced breast cancer (stage III)**
- o Metastatic breast cancer (stage IV)**

We do not hold this information. You may wish to redirect your request to the main provider of

the breast service, North Bristol NHS Trust - [foi@nbt.nhs.uk](mailto:foi@nbt.nhs.uk)

**3. How many patients with breast cancer were treated in the following categories of tumour characteristics and staging?**

- **Early breast cancer Neoadjuvant HR+ve (ER+ve &/or PR+ve)**
- **Early breast cancer Adjuvant HR+ve (ER+ve &/or PR+ve)**
- **Early breast cancer Neoadjuvant HR+ve, HER2+ve**
- **Early breast cancer Adjuvant HR+ve, HER2+ve**
- **Early breast cancer Neoadjuvant HR+ve, HER2-ve**
- **Early breast cancer Adjuvant HR+ve, HER2-ve**
- **Early breast cancer Neoadjuvant HR+ve, HER2-ve, node positive**
- **Early breast cancer Adjuvant HR+ve, HER2-ve, node positive**
- **Early breast cancer Neoadjuvant HER2+ve, node positive**
- **Early breast cancer Adjuvant HER2+ve, node positive**
- **Early breast cancer Neoadjuvant BRCA1/2 germline mutation positive**
- **Early breast cancer Adjuvant BRCA1/2 germline mutation positive**
- **Early breast cancer Neoadjuvant Triple negative**
- **Early breast cancer Adjuvant Triple negative**
- **Early breast cancer All PIK3CA mutation**
- **Locally advanced All HR+ve (ER+ve &/or PR+ve)**
- **Locally advanced All HER2+ve**
- **Locally advanced All HR+ve, HER2-ve**
- **Locally advanced All BRCA1/2 germline mutation positive**
- **Locally advanced All Triple negative, PD-L1 positive**
- **Locally advanced All Triple negative, PD-L1 negative**
- **Locally advanced All PIK3CA mutation**
- **Metastatic All HR+ve (ER+ve &/or PR+ve)**
- **Metastatic All HER2+ve**
- **Metastatic All HR+ve, HER2-ve**
- **Metastatic All BRCA1/2 germline mutation positive**
- **Metastatic All Triple negative, PD-L1 positive**
- **Metastatic All Triple negative, PD-L1 negative**
- **Metastatic All PIK3CA mutation**

We do not hold this information. You may wish to redirect your request to the main provider of the breast service, North Bristol NHS Trust - [foi@nbt.nhs.uk](mailto:foi@nbt.nhs.uk)

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer

University Hospitals Bristol and Weston NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

#### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**